I bet you don't own or own very few biotechs that generate sales already.
Correct. Of the nine, Medivir is the only one that has any actual sales (had sales before recent launch of Olysio). At about $400M market cap, it also has the largest market cap of any of my holdings.
It has been rather clear to me for quite some time that most acquirers have been focused on acquiring companies with approved products already.